Evidence of mast cell activation and leukotriene release after mannitol inhalation Source: Eur Respir J 2003; 22: 491-496 Year: 2003
Inhibition of the airway response to mannitol with either eformoterol or sodium cromoglycate (SCG) does not alter leukotriene release in asthmatic subjects Source: Eur Respir J 2004; 24: Suppl. 48, 443s Year: 2004
Interactive inhibitory effects of formoterol and montelukast on activated human neutrophils Source: Eur Respir J 2010; 36: 1417-1424 Year: 2010
Inhalation of mannitol, used as a model for exercise-induced bronchoconstriction (EIB), causes release of leukotrienes and a mast cell marker in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 102s Year: 2001
Formoterol protects against platelet-activating factor-induced effects in asthma Source: Eur Respir J 2004; 23: 71-75 Year: 2004
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
A leukotriene antagonist, montelukast, reduces in vitro LTD4 increases in peripheral blood eosinophil progenitor colonies in atopic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 531s Year: 2001
The effects of a cysteinyl leukotriene receptor antagonist, pranlukast, on dendritic cell chemoattractants in the airways of subjects with asthma Source: Eur Respir J 2004; 24: Suppl. 48, 132s Year: 2004
IL-1β-induced MCP-1 production in human airway smooth muscle cells, modulation by dexamethasone, rolipram, and salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 353s Year: 2001
Prostaglandin D2 (PGD2 ) and tryptase release into blood after adenosine and methacholine challenges in asthmatic patients Source: Eur Respir J 2006; 28: Suppl. 50, 670s Year: 2006
The effect of a leukotriene antagonist, pranlukast, on allergen-induced airway responses and circulating dendritic cells in subjects with atopic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003
Montelukast protects against nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: 226-230 Year: 2004
Quantitative assessment of cysteinyl leukotrienes in human sputum during the allergen-induced asthmatic response and the effect of GSK2190915, a 5-lipoxygenase activating protein (FLAP) inhibitor Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases Year: 2011
Inhibition of eosinophil migration by montelukast, a cysteinyl leukotriene receptor antagonist, through down regulation of plasmin activity Source: Eur Respir J 2004; 24: Suppl. 48, 36s Year: 2004
Effect of combined leukotriene, histamine antagonism on the early response to inhaled allergen Source: Eur Respir J 2005; 26: Suppl. 49, 583s Year: 2005
Dissociation of airway inflammation and hyperresponsiveness by cyclooxygenase inhibition in allergen challenged mice Source: Eur Respir J 2009; 34: 200-208 Year: 2009
Prostaglandin E2 prevents mast cell dependent bronchoconstrictrion via the EP2 receptor in human small airways Source: International Congress 2015 – Novel mechanisms and treatments in allergy and asthma Year: 2015
Intranasal administration of leukotriene B4 selectively increases human nasal neutrophil activity Source: Annual Congress 2008 - Phenotyping of asthma and COPD Year: 2008
Bronchoconstriction induced by prostaglandin D2 (PGD2 ) in guinea pig lung is enhanced by selective COX-2 inhibition Source: Eur Respir J 2006; 28: Suppl. 50, 759s Year: 2006